×
Back to Agenda
Session 1 Track C: Pharmacovigilance and Risk Management Post-Pandemic: Lessons Learned and Future Perspectives
Session Chair(s)
Marilyne Chamoun, MSC
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau, Health Canada, Canada
Patrick Fandja, MBA, MS
Director, Bureau of Biologics, Radiopharmaceuticals and Self-care products, Health Canada, Canada
In this session, representatives from regulatory agencies (EMA, FDA and Health Canada) will discuss their perspectives on lessons learned from the pandemic, and how they will shape the future of pharmacovigilance and risk management planning.
Learning Objective : At the conclusion of this session, participants should be able to:
- Gain a global understanding of the lessons learned from the pandemic
- Identify changes to PV/RM practices that should be adopted/considered post-pandemic
Speaker(s)
Kate A Browne, MSC, RPH
Signal Management Lead, European Medicines Agency, Netherlands
Speaker
Gerald Dal Pan, MD, MHS
Director, Office of Surveillance and Epidemiology, CDER, FDA, United States
Speaker
Kelly Robinson, MSC
Director General, Pharmaceutical Drugs Directorate, Health Canada, Canada
Speaker
Have an account?